{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:20:31Z","timestamp":1791109231839,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.clinthera.2009.09.013","type":"journal-article","created":{"date-parts":[[2009,10,19]],"date-time":"2009-10-19T08:03:24Z","timestamp":1255939404000},"page":"1887-1907","source":"Crossref","is-referenced-by-count":18,"title":["Romiplostim in chronic immune thrombocytopenic purpura"],"prefix":"10.1016","volume":"31","author":[{"given":"Robert J.","family":"Cersosimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.09.013_bib1","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.clinthera.2009.09.013_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1067\/mpd.2000.110123","article-title":"The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment","volume":"137","author":"Dickerhoff","year":"2000","journal-title":"J Pediatr."},{"key":"10.1016\/j.clinthera.2009.09.013_bib4","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(01)07219-1","article-title":"Newly diagnosed idiopathic thrombocytopenic purpura in childhood: An observational study","volume":"358","author":"K\u00fchne","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.09.013_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"George","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","article-title":"The incidence of idiopathic thrombocytopenic purpura in adults increases with age","volume":"94","author":"Frederiksen","year":"1999","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a populationbased cohort of 245 patients","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","year":"2003","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood-2004-09-3418","article-title":"Is immune thrombocytopenic purpura less common among black Americans?","volume":"105","author":"Terrell","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1182\/blood-2006-03-010405","article-title":"Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans","volume":"108","author":"Landgren","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V59.1.23.23","article-title":"Specificity of autoantibodies in autoimmune thrombocytopenia","volume":"59","author":"van Leeuwen","year":"1982","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1538-7836.2003.00091.x","article-title":"Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP)","volume":"1","author":"McMillan","year":"2003","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.clinthera.2009.09.013_bib14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopaenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V88.1.194.194","article-title":"Prospective evaluation of the clinical usefulness of an antigenspecific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias","volume":"88","author":"Brighton","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI4238","article-title":"Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody","volume":"102","author":"Kuwana","year":"1998","journal-title":"J Clin Invest."},{"key":"10.1016\/j.clinthera.2009.09.013_bib18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib19","first-page":"356","article-title":"Chronic idiopathic thrombocytopenic purpura: Present strategy, guidelines and new insights","volume":"64","author":"Stevens","year":"2006","journal-title":"Neth J Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4065\/79.4.504","article-title":"Management of immune thrombocytopenic purpura in adults","volume":"79","author":"Stasi","year":"2004","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.clinthera.2009.09.013_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM199411033311807","article-title":"Chronic idiopathic thrombocytopenic purpura","volume":"331","author":"George","year":"1994","journal-title":"N Engl J Med."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2009.09.013_bib22","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/sj.thj.6200414","article-title":"Idiopathic thrombocytopenic purpura in adults: Current issues for pathogenesis, diagnosis and management","volume":"5","author":"George","year":"2004","journal-title":"Hematol J."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.09.013_bib23","first-page":"36","article-title":"Management of chronic immune thrombocytopenic purpura in children and adults","volume":"35","author":"Blanchette","year":"1998","journal-title":"Semin Hematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V82.5.1415.bloodjournal8251415","article-title":"Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin","volume":"82","author":"Godeau","year":"1993","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1423-0410.1987.tb03029.x","article-title":"Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: Review of the literature","volume":"52","author":"Bussel","year":"1987","journal-title":"Vox Sang."},{"key":"10.1016\/j.clinthera.2009.09.013_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)07275-6","article-title":"Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial","volume":"359","author":"Godeau","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.09.013_bib27","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.V77.9.1884.1884","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect","volume":"77","author":"Bussel","year":"1991","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V89.8.2689","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients","volume":"89","author":"Scaradavou","year":"1997","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1046\/j.1365-2141.2001.02627.x","article-title":"A dose of 75 microg\/kg\/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg\/kg\/d in adults with immune thrombocytopenic purpura","volume":"112","author":"Newman","year":"2001","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib30","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.09.013_bib31","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2146\/ajhp080493","article-title":"New options after firstline therapy for chronic immune thrombocytopenic purpura","volume":"66","author":"Burzynski","year":"2009","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.clinthera.2009.09.013_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-140-3-200402030-00012","article-title":"Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: A systematic review","volume":"140","author":"Vesely","year":"2004","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib33","series-title":"Nplate (romiplostim) [prescribing information]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.09.013_bib34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.09.013_bib35","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0091270007306563","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study","volume":"47","author":"Kumagai","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06339.x","article-title":"An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura","volume":"135","author":"Newland","year":"2006","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib37","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesisstimulating protein, for chronic ITP [published correction appears in N Engl J Med. 2006;355:2054]","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1651-2227.1998.tb01227.x","article-title":"The Mpl ligand and platelet homeostasis","volume":"424","author":"Nichol","year":"1998","journal-title":"Acta Paediatr Suppl."},{"key":"10.1016\/j.clinthera.2009.09.013_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.09.013_bib41","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP [published correction appears in Blood. 2009;113:4822]","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.09.013_bib43","article-title":"Phase 1\/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): Update including extended treatment","volume":"110","author":"Kantarjian","year":"2007"},{"key":"10.1016\/j.clinthera.2009.09.013_bib45","article-title":"Low immunogenicity to romiplostim in clinical studies with ITP subjects","volume":"112","author":"Jawa","year":"2008"},{"key":"10.1016\/j.clinthera.2009.09.013_bib46","article-title":"Evaluation of bone marrow reticulin formation in romiplostim-treated adult patients with chronic immune thrombocytopenic purpura (ITP)","volume":"112","author":"Kuter","year":"2008"},{"key":"10.1016\/j.clinthera.2009.09.013_bib47","first-page":"1241","article-title":"Normal reticulin level in iliac bone marrow","volume":"114","author":"Beckman","year":"1990","journal-title":"Arch Pathol Lab Med."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.09.013_bib48","first-page":"80","article-title":"Bone marrow reticulin in patients with immune thrombocytopenic purpura","volume":"5","author":"Mufti","year":"2007","journal-title":"J Support Oncology."},{"key":"10.1016\/j.clinthera.2009.09.013_bib49","article-title":"Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP)","volume":"112","author":"Liebman","year":"2008"},{"key":"10.1016\/j.clinthera.2009.09.013_bib51","article-title":"Self-injection of romiplostim by patients with chronic immune thrombocytopenic purpura (ITP)","volume":"112","author":"George","year":"2008"},{"key":"10.1016\/j.clinthera.2009.09.013_bib52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1548-5315(11)70192-9","article-title":"Romiplostim: The risk evaluation and mitigation strategy (REMS)","volume":"5","author":"Newton","year":"2008","journal-title":"Comm Oncol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: Results of two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib56","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1517\/14712598.8.7.1021","article-title":"The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes","volume":"8","author":"Tiu","year":"2008","journal-title":"Expert Opin Biol Ther."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.09.013_bib57","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminhematol.2008.12.007","article-title":"Management of chemotherapy-induced thrombocytopenia: Current status of thrombopoietic agents","volume":"46","author":"Vadhan-Raj","year":"2009","journal-title":"Semin Hematol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2009.09.013_bib59","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1548-5315(11)70191-7","article-title":"Finding a place for thrombopoietin receptor agonists in the treatment of chronic ITP","volume":"5","author":"Pullarkat","year":"2008","journal-title":"Comm Oncol."},{"key":"10.1016\/j.clinthera.2009.09.013_bib60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0037-1616946","article-title":"Chronic immune thrombocytopenic purpura. New agents","volume":"29","author":"Rodeghiero","year":"2009","journal-title":"Hamostaseologie."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T03:35:25Z","timestamp":1590204925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0149291809003427"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.09.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}